This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Agenus Only Gets A Mosquito-Sized Bite of the New And Heralded Malaria Vaccine

LEXINGTON, Mass. ( TheStreet) --A new, experimental malaria vaccine from GlaxoSmithKline (GSK - Get Report) is great news for the children of Africa, not so much for Agenus (AGEN - Get Report).

Glaxo's malaria vaccine halved the risk of African children getting the mosquito-borne disease in a large clinical trial. Bill Gates and other global health officials heralded the vaccine trial results as an unprecedented achievement that will save countless lives.

Investors read the news and sent shares of Agenus soaring by as much as 60% to $4.43 Tuesday based on a misguided notion that the cash-burning, money-losing drug maker will profit off its small part in developing the Glaxo malaria vaccine.

That's not likely to happen. Indeed, Agenus makes the immune system-boosting ingredient that's part of the Glaxo malaria vaccine. And Agenus will receive low single-digit royalty on sales of the malaria vaccine.

Which is where Agenus' party ends. Glaxo wants to be perceived as a good global citizen, so it's basically giving away the malaria vaccine. The exact cost of the vaccine hasn't been disclosed but $10 per course of treatment is the rumored price tag.

Glaxo has pledged to price the malaria vaccine as low as possible. "We're not going to make any money from this project," said Glaxo CEO Andrew Witty, according to Reuters.

In 2009, Agenus, then known as Antigenics, disclosed that its royalty rate for the QS21 adjuvant under the Glaxo agreement ranged from $1.5% to 6%, depending on the vaccine, but was generally in the low-single digits.

If Glaxo is pledged to generate no profit from the malaria vaccine, it’s probably safe to assume that Agenus' royalty is on the low end, or 1.5%. That means for every $10 treatment course sold, Agenus' share would come to 15 cents.

Malaria kills about 800,000 people every year. If 1 million people were vaccinated with the vaccine, Glaxo sales would total $10 million; Agenus' share would be $150,000.

The World Health Organization reports 225 million cases of malaria in 2010. If every infected person had been vaccinated to prevent infection in the first place, Glaxo's malaria vaccine could theoretically generate $2.25 billion in sales.

Agenus' share of that blockbuster vaccine would be just $34 million.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AGEN $5.11 0.00%
GSK $40.51 0.00%
AAPL $118.30 0.00%
FB $104.24 0.00%
GOOG $742.60 0.00%


Chart of I:DJI
DOW 17,719.92 -78.57 -0.44%
S&P 500 2,080.41 -9.70 -0.46%
NASDAQ 5,108.6660 -18.8590 -0.37%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs